Evidence map›Paper›PMID 40612183›Full record

ArticleSage open pediatrics

A Longitudinal Observational Study of a Powder-Based Supplement for a Future Synbiotic Trial in Breastfed Children From South Africa.

Rupak Shivakoti, Barbara Laughton, Mehr Shafiq, Elisma Schoeman, Richard H Glashoff, Shaun Barnabas, Samantha Fry, Cheng-Shiun Leu, Shuang Wang, Lars Bode and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sage open pediatrics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Rupak ShivakotiDepartment of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-2773-9310
Barbara LaughtonFaculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Mehr ShafiqDepartment of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Elisma SchoemanFaculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Richard H GlashoffStellenbosch University and National Health Laboratory Service, Cape Town, South Africa.
Shaun BarnabasFaculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Samantha FryFaculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Cheng-Shiun LeuDepartment of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Shuang WangDepartment of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Lars BodeUniversity of California, San Diego, CA, USA.
Grace AldrovandiDavid Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Louise KuhnDepartment of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Amy L SlogroveFaculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Funding

Trial of Human Milk Oligosaccharide-based synbiotics for HIV-exposed uninfected childrenR01HD105492 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHIVAKOTI, RUPAK · 2021 to 2025
$3.9M
NICHD NIH HHS R01 HD105492
6 · The paper itself

Abstract

This study investigates the feasibility and acceptability of a powder-based supplement for breastfeeding HIV-exposed uninfected children to inform a larger trial (MIGH-T MO study). Ten mothers living with HIV and their children (6 weeks-20 months) at Tygerberg Hospital, Cape Town, South Africa, participated. The children received a daily supplement of potato maltodextrin mixed with expressed breast milk for 4 weeks, serving as a placebo control for the upcoming trial. Outcomes assessed included feasibility, acceptability, adherence, and health effects, evaluated at enrollment, during weekly calls, and at the 4-week visit. High acceptability was indicated by full enrollment of eligible participants, though there was some loss to follow-up (n = 3). Among the remaining participants, no major feasibility issues were found regarding procedures, product administration, adherence, tolerance, or health assessments. The study concludes that powder-based supplements are feasible and acceptable for breastfeeding HEU children, supporting the potential for larger studies using similar supplements.

Indexed as

breastmilkchild morbidityfeasibilityHMOsynbiotic

Identifiers

PMID40612183
PMCPMC12219489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.